PPARG and neoplasm: Interestingly, nuclearexpression of PPARγ was significantly reduced in a majority of the patientswhose pre-rosiglitazone PPARγ scores were 1+ or 2+ and therefore assessable forincreased or decreased levels of expression, which raised the possibility of aPPARγ mediated response in the tumor tissue.